Novo Nordisk CEO Lars Sørensen: An Interview With "The Pink Sheet"

Novo Nordisk AS turned in a strong financial showing in 2010, with sales up 13%, and the Danish company has been riding a wave of positive investor sentiment. The launch of the once-daily GLP-1 analogue Victoza (liraglutide) in the U.S. in the early part of the year helped to drive sales, but its modern insulins portfolio also continues to perform well.